Poly(pyrrolidone) Oligomers for Low-Toxicity Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current polymer technologies, such as PEGylation and POXylation, face challenges with oxidative stability, immunogenicity, and high molecular weight fractions that lead to accumulation in vivo, particularly with PVP polymers, which can cause diseases like Dupont-Lachapelle Disease, and traditional fluorophores suffer from photobleaching and toxicity issues.
Innovation Solution
Development of low molecular weight poly(pyrrolidone) oligomers and polymers with intrinsic fluorescence properties, controlled molecular weights, and non-immunogenicity, which can be used for PYRROLIDONylation of biological substrates, offering alternatives to PEGylation and POXylation, and exhibiting enhanced fluorescence for imaging and drug delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If high molecular weight PVP fractions are used for injectable applications, then blood circulation time and drug solubility are enhanced, but in vivo accumulation occurs leading to Dupont-Lachapelle Disease
Solution Approach 1:
The patent applies parameter changes by precisely controlling the molecular weight of PVP polymers to be below 70 KDa (specifically 10-50 KDa), which fundamentally changes the excretion capability of the polymer. This parameter control allows the polymer to be efficiently cleared by renal filtration while maintaining sufficient blood circulation time and drug solubility enhancement, thereby resolving the contradiction between prolonged circulation and in vivo accumulation.
2Illumination intensity
If traditional fluorophores are used for imaging, then fluorescence signal is obtained, but photobleaching and toxicity issues occur
Solution Approach 1:
The patent employs composite materials by combining PVP polymers with fluorescent moieties to create a hybrid imaging agent. The PVP component provides biocompatibility, solubility, and resistance to photobleaching, while the fluorescent component delivers the imaging signal. This composite approach allows the system to maintain fluorescence signal intensity while eliminating the photobleaching and toxicity problems associated with traditional fluorophores.
3Reliability
If PEGylation is used to reduce immunogenicity, then blood circulation time is enhanced, but oxidative instability and immunogenicity problems persist
Solution Approach 1:
The patent applies the extraction principle by removing the vulnerable PEG component from the conjugate structure and replacing it with PVP polymers. This substitution extracts the oxidative stability and immunogenicity resistance properties from PEG and transfers them to the PVP-based conjugate, while maintaining the blood circulation time enhancement benefits. The PVP structure inherently resists oxidative degradation and reduces immunogenicity without the stability issues of PEG.
4Stability of the object's composition
If POXylation is used as alternative to PEGylation, then oxidative stability is improved, but immunogenicity and molecular weight control issues remain
Solution Approach 1:
The patent applies this principle by using low molecular weight PVP polymers (10-50 KDa) that are rapidly cleared from the body through renal filtration. This 'short-living' approach ensures that the polymer does not accumulate in vivo, reducing immunogenicity risks. The low molecular weight design allows for better control over pharmacokinetics and reduces the immunogenicity associated with higher molecular weight polymers, while maintaining oxidative stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These poly(pyrrolidone) compositions demonstrate low toxicity, controlled molecular weights, and non-immunogenicity, enabling safe in vivo use and effective imaging and drug delivery while avoiding the limitations of traditional fluorophores and high molecular weight polymer accumulation.
Implementation Method 1
the new poly(pyrrolidone) oligomers/polymers obtained from these derivatives exhibit unique intrinsic fluorescence (IF) or non-traditional fluorescence (NTF) properties
Data Source
AI summary
Simple organic structures, organic/inorganic polymers, and other substrates have been made, all of which have at least one pyrrolidone moiety present, and found to exhibit low toxicity, low complement activation features and may be used to reduce protein interactions with drug conjugates while enhancing in vivo residency times for these conjugates when used as an injectable composition; thus these compounds can be used as substitutes for PEG in PEGylation. Surprisingly, these compounds also exhibit unique intrinsic fluorescence (IF) or non-traditional fluorescence (NTF) properties that currently cannot be explained by traditional photochemistry and fluorescence paradigms are described. These compounds have a variety of applications such as in cellular imaging, gene transfection, bio-diagnostics, biosensing, fluorescence directed surgical resections, drug delivery, forensics, environmental diagnostics, mineral/gemstone characterization, counterfeit goods detection, tracer studies related to liquid/water flow, oil field enhancements and diagnostics, prevention of photo-bleaching, and LED display enhancements and others.